Lithium-Associated Hyperthyroidism Treated With Lithium Withdrawal: A Case Report
Publication: American Journal of Psychiatry
To the Editor: Lithium, a first-line treatment for bipolar disorder, is a well-known cause of hypothyroidism; however, case reports have documented the emergence of thyrotoxicosis during lithium treatment, with evidence showing the incidence rate to be greater than expected in the general population (1–3). The recommended conservative management is antithyroid medication and continuation of lithium (4). It is advised that lithium not be withdrawn because of several reports of exacerbation of thyrotoxicosis (1, 2, 5). We report the case of a patient with lithium-associated hyperthyroidism treated with drug withdrawal, a treatment method documented in only one previous case (6).
“Mr. A,” a 61-year-old man with bipolar disorder, had been treated with lithium and haloperidol for 7 years. His thyroid function test results were normal in January 2009. Routine testing in August 2010 revealed a low therapeutic lithium level (0.50 mmol/L [normal range=0.50–1.50]) and a low thyroid-stimulating hormone (TSH) level (0.02 mU/L [0.34–5.60]). A thyroid function panel drawn 5 days later revealed low TSH (0.03 mU/L), elevated free thyroxine (1.73 ng/dL [0.58–1.64]), and elevated free triiodothyronine (4.8 pg/mL [2.4–4.2]). Results of tests for thyroid antibodies were negative. The patient was asymptomatic, and findings on a physical examination were normal. A thyroid uptake scan showed a 24-hour 131I uptake of 3.8% (normal range=7–33), normal gland size, and heterogeneous tracer activity, consistent with thyroiditis. Because of the thyroid dysfunction as well as borderline renal function (creatinine 1.3 mg/dL [0.5–1.3]), lithium was tapered off (from 600 mg/day to 300 mg/day for 7 days and then off). The patient was maintained on haloperidol monotherapy, which was titrated up. Four weeks later, the patient's free thyroxine level had normalized (0.87 ng/dL).
Theories that lithium causes hyperthyroidism include induction of autoimmunity and direct toxic effect causing thyroid hormone release (4). Notably, the three reports of exacerbation of thyrotoxicosis after withdrawal of lithium were in patients with Graves' disease. Conversely, our patient, who presented with thyroiditis, improved after withdrawal of lithium, which is consistent with the theory of lithium's direct toxic effect on thyrocytes. One could conclude that management of lithium-associated hyperthyroidism would differ based on the etiology of the thyroid overactivity. Our case suggests that patients who present with thyroiditis can be effectively treated with withdrawal of lithium.
Footnote
Accepted for publication in December 2010.
References
1.
Schoenberg M, Ts'o TO, Meisel AN: Graves' disease manifesting after maintenance lithium. J Nerv Ment Dis 1979; 167:575–577
2.
Rosser R: Thyrotoxicosis and lithium. Br J Psychiatry 1976; 128:61–66
3.
Miller KK, Daniels GH: Association between lithium use and thyrotoxicosis caused by silent thyroiditis. Clin Endocrinol 2001; 55:501–508
4.
Meurisse M, Gollogly L, Degaugque C, Fumal I, Defechereux T, Hamoir E: Iatrogenic thyrotoxicosis: causal circumstances, pathophysiology, and principles of treatment: review of the literature. World J Surg 2000; 24:1377–1385
5.
Thompson CJ, Baylis PH: Asymptomatic Graves' disease during lithium therapy. Postgrad Med J 1978; 62:295–296
6.
Rabin PL, Evans DC: Exophthalmos and elevated thyroxine levels in association with lithium therapy. J Clin Psychiatry 1981; 48:398–400
Information & Authors
Information
Published In
History
Accepted: December 2010
Published online: 1 April 2011
Published in print: April 2011
Authors
Funding Information
The authors report no financial relationships with commercial interests.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).